CRISPR Therapeutics AGCRSP -3.21%41 Days Payable is 24.61 as of Mar. 2026, which is 65% below its 10-year median of 69.93. GuruFocus rates CRSP with a GF Score™ of 41/100 and a GF Value™ of $2.70 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, CRISPR Therapeutics AG ranks worse than 88.21% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CRISPR Therapeutics AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Days Payable distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CRISPR Therapeutics AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (CRSP) has a Days Payable of 24.61 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CRISPR Therapeutics AG and its competitors. This is 65% below median its historical median of 69.93. Over the past decade, CRISPR Therapeutics AG's Days Payable has ranged from 21.47 to 91.88. According to the industry distribution chart, CRISPR Therapeutics AG ranks #621 out of 704 companies in the Biotechnology industry, placing it in the top 88.2%.
Is CRISPR Therapeutics AG's Days Payable too high?
CRISPR Therapeutics AG's current Days Payable of 24.61 is 65% below median its 10-year median of 69.93. Over the past 10 years, this metric has ranged from a low of 21.47 to a high of 91.88. The Biotechnology industry median Days Payable is 113.56. CRISPR Therapeutics AG's value of 24.61 is 78.3% below this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #621 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Days Payable compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #621 out of 704 companies for Days Payable. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median Days Payable is 113.56. CRISPR Therapeutics AG's value of 24.61 is 78.3% below this benchmark. Historically, CRISPR Therapeutics AG's own Days Payable has ranged from 21.47 to 91.88 over the past decade. While the company's 10-year median is 69.93 vs. the industry median of 113.56, CRISPR Therapeutics AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current Days Payable of 24.61 is 78.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CRISPR Therapeutics AG and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Days Payable is 24.61, which is 65% below median its own 10-year median of 69.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.70, compared to a current price of $54.54 — trading 1920% above its estimated fair value. The current Days Payable is 24.61, which is 65% below median its 10-year median of 69.93 and 78.3% below the Biotechnology industry median of 113.56. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Days Payable is 24.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $54.54 is trading 1920% above its estimated GF Value™ of $2.70.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for CRSP:
Days Payable: 24.61 (65% below median its 10-year median of 69.93)
GF Value™: $2.70 vs. price of $54.54 (1920% above fair value)
Industry Position: 78.3% below the Biotechnology median (#621 of 704)
No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score
Get the complete analysis for CRSP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRSP has been successfully added to your 
